Skip to main content
European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Zawartość zarchiwizowana w dniu 2024-06-18

Evaluation of antibiotics (ciprofloxacin and fluconazole) for the treatment of infections in preterm and term neonates

Cel

The aim of TINN is to evaluate ciprofloxacin, fluconazole and micafungin in neonates; two anti-infectious drugs included in the EMEA priority list of the therapeutic areas that need specific drug evaluation in preterm and term neonates. These drugs are prescribed off-label to treat neonatal infections that are life threatening situations and associated with long-term complications. In order to validate the use of these two drugs in these high risk populations, TINN involves European leaders in neonatology, paediatric pharmacology, methodology and SME and has established a close collaboration between academia, ethical bodies, regulatory authorities and pharmaceutical companies. For both drugs, the project will perform in silico experimentations, animal studies and evaluate formulations adapted to neonates. Designs will be optimized using age-appropriate state-of-the-art methods adapted to neonates, include pharmacokinetics and pharmacogenetics in order to validate the components of a Paediatric Investigation Plan. The two trials will be performed with neonatologists trained in paediatric pharmacology and clinical research who respect Good Clinical Practices. All the ethical issues related to the two trials will be considered in particular pain and distress, blood sampling (number and volume) and informed consent. Parent information sheets and consent form submitted to parents’ associations for approval. TINN will include short-term safety (based on vital signs, blood safety data and function of the major
organs) and potential for long-term adverse reactions. Results will be also reported in order to allow a PUMA application and to improve neonatal care, through scientific societies. Therefore, TINN will strengthen the European role in drug evaluation in paediatric patients and will support initiatives of the European pharmaceutical industry. Increasing the appropriate use of medicines in child will be of direct benefit to children, their families and health professionals.

Zaproszenie do składania wniosków

FP7-HEALTH-2007-B
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Wkład UE
€ 1 277 401,00
Adres
RUE DE TOLBIAC 101
75654 Paris
Francja

Zobacz na mapie

Region
Ile-de-France Ile-de-France Paris
Rodzaj działalności
Research Organisations
Kontakt administracyjny
Isabelle Pires (Ms.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (15)